UNLABELLED: By linking surgeon surveys to the National Cancer Database, we found that surgeons' tendency to perform more extensive thyroid resection is associated with greater use of radioactive iodine for stage I thyroid cancer. OBJECTIVE: To determine the relationships between surgeon recommendations for extent of resection and radioactive iodine use in low-risk thyroid cancer. BACKGROUND: There has been an increase in thyroid cancer treatment intensity; the relationship between extent of resection and medical treatment with radioactive iodine remains unknown. METHODS: We randomly surveyed thyroid surgeons affiliated with 368 hospitals with Commission on Cancer-accredited cancer programs. Survey responses were linked to the National Cancer Database. The relationship between extent of resection and the proportion of the American Joint Committee on Cancer stage I well-differentiated thyroid cancer patients treated with radioactive iodine after total thyroidectomy was assessed with multivariable weighted regression, controlling for hospital and surgeon characteristics. RESULTS: The survey response rate was 70% (560/804). Surgeons who recommend total thyroidectomy over lobectomy for subcentimeter unifocal thyroid cancer were significantly more likely to recommend prophylactic central lymph node dissection for thyroid cancer regardless of tumor size (P < 0.001). They were also more likely to favor radioactive iodine in patients with intrathyroidal unifocal cancer ≤1 cm (P = 0.001), 1.1-2 cm (P = 0.004), as well as intrathyroidal multifocal cancer ≤1 cm (P = 0.004). In multivariable analysis, high hospital case volume, fewer surgeon years of experience, general surgery specialty, and preference for more extensive resection were independently associated with greater hospital-level use of radioactive iodine for stage I disease. CONCLUSIONS: In addition to surgeon experience and specialty, surgeons' tendency to perform more extensive thyroid resection is associated with greater use of radioactive iodine for stage I thyroid cancer.
UNLABELLED: By linking surgeon surveys to the National Cancer Database, we found that surgeons' tendency to perform more extensive thyroid resection is associated with greater use of radioactive iodine for stage I thyroid cancer. OBJECTIVE: To determine the relationships between surgeon recommendations for extent of resection and radioactive iodine use in low-risk thyroid cancer. BACKGROUND: There has been an increase in thyroid cancer treatment intensity; the relationship between extent of resection and medical treatment with radioactive iodine remains unknown. METHODS: We randomly surveyed thyroid surgeons affiliated with 368 hospitals with Commission on Cancer-accredited cancer programs. Survey responses were linked to the National Cancer Database. The relationship between extent of resection and the proportion of the American Joint Committee on Cancer stage I well-differentiated thyroid cancerpatients treated with radioactive iodine after total thyroidectomy was assessed with multivariable weighted regression, controlling for hospital and surgeon characteristics. RESULTS: The survey response rate was 70% (560/804). Surgeons who recommend total thyroidectomy over lobectomy for subcentimeter unifocal thyroid cancer were significantly more likely to recommend prophylactic central lymph node dissection for thyroid cancer regardless of tumor size (P < 0.001). They were also more likely to favor radioactive iodine in patients with intrathyroidal unifocal cancer ≤1 cm (P = 0.001), 1.1-2 cm (P = 0.004), as well as intrathyroidal multifocal cancer ≤1 cm (P = 0.004). In multivariable analysis, high hospital case volume, fewer surgeon years of experience, general surgery specialty, and preference for more extensive resection were independently associated with greater hospital-level use of radioactive iodine for stage I disease. CONCLUSIONS: In addition to surgeon experience and specialty, surgeons' tendency to perform more extensive thyroid resection is associated with greater use of radioactive iodine for stage I thyroid cancer.
Authors: David T Hughes; Matthew L White; Barbra S Miller; Paul G Gauger; Richard E Burney; Gerard M Doherty Journal: Surgery Date: 2010-12 Impact factor: 3.982
Authors: Andrew W Dick; Melony S Sorbero; Gretchen M Ahrendt; James A Hayman; Heather T Gold; Linda Schiffhauer; Azadeh Stark; Jennifer J Griggs Journal: J Natl Cancer Inst Date: 2011-01-03 Impact factor: 13.506
Authors: Steven J Katz; Sarah T Hawley; Paul Abrahamse; Monica Morrow; Christopher R Friese; Amy K Alderman; Jennifer J Griggs; Ann S Hamilton; John J Graff; Timothy P Hofer Journal: Med Care Date: 2010-10 Impact factor: 2.983
Authors: Karl Y Bilimoria; David J Bentrem; John G Linn; Andrew Freel; Jen Jen Yeh; Andrew K Stewart; David P Winchester; Clifford Y Ko; Mark S Talamonti; Cord Sturgeon Journal: Surgery Date: 2007-11-05 Impact factor: 3.982
Authors: Kathryn M Schuessler; Mousumi Banerjee; Di Yang; Andrew K Stewart; Gerard M Doherty; Megan R Haymart Journal: Ann Surg Oncol Date: 2012-12-06 Impact factor: 5.344
Authors: Megan R Haymart; Mousumi Banerjee; Di Yang; Andrew K Stewart; James C Sisson; Ronald J Koenig; Gerard M Doherty; Jennifer J Griggs Journal: J Clin Endocrinol Metab Date: 2013-03-28 Impact factor: 5.958
Authors: Megan R Haymart; Mousumi Banerjee; Di Yang; Andrew K Stewart; Jennifer J Griggs; James C Sisson; Ronald J Koenig Journal: Endocr Pract Date: 2013 Jul-Aug Impact factor: 3.443
Authors: Maria Papaleontiou; Mousumi Banerjee; Di Yang; James C Sisson; Ronald J Koenig; Megan R Haymart Journal: Thyroid Date: 2013-02 Impact factor: 6.568
Authors: Joshua M Evron; David Reyes-Gastelum; Mousumi Banerjee; Laura D Scherer; Lauren P Wallner; Ann S Hamilton; Kevin C Ward; Sarah T Hawley; Brian J Zikmund-Fisher; Megan R Haymart Journal: J Clin Oncol Date: 2019-10-01 Impact factor: 50.717
Authors: Alexandria D McDow; Benjamin R Roman; Megan C Saucke; Catherine B Jensen; Nick Zaborek; Jamia Linn Jennings; Louise Davies; Juan P Brito; Susan C Pitt Journal: Am J Surg Date: 2020-11-12 Impact factor: 3.125
Authors: Lauren P Wallner; Mousumi Banerjee; David Reyes-Gastelum; Ann S Hamilton; Kevin C Ward; Carrie Lubitz; Sarah T Hawley; Megan R Haymart Journal: J Clin Endocrinol Metab Date: 2021-05-13 Impact factor: 5.958